BR112014012137A2 - anticorpos anti-fgfr2 e suas utilizações - Google Patents
anticorpos anti-fgfr2 e suas utilizaçõesInfo
- Publication number
- BR112014012137A2 BR112014012137A2 BR112014012137A BR112014012137A BR112014012137A2 BR 112014012137 A2 BR112014012137 A2 BR 112014012137A2 BR 112014012137 A BR112014012137 A BR 112014012137A BR 112014012137 A BR112014012137 A BR 112014012137A BR 112014012137 A2 BR112014012137 A2 BR 112014012137A2
- Authority
- BR
- Brazil
- Prior art keywords
- fgfr2 antibodies
- fgfr2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11190227 | 2011-11-23 | ||
| PCT/EP2012/073325 WO2013076186A1 (en) | 2011-11-23 | 2012-11-22 | Anti-fgfr2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014012137A2 true BR112014012137A2 (pt) | 2017-05-30 |
Family
ID=47278276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014012137A BR112014012137A2 (pt) | 2011-11-23 | 2012-11-22 | anticorpos anti-fgfr2 e suas utilizações |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140322220A1 (pt) |
| EP (1) | EP2782934A1 (pt) |
| JP (1) | JP2015504434A (pt) |
| KR (1) | KR20140102698A (pt) |
| CN (1) | CN104066750B (pt) |
| AR (1) | AR088941A1 (pt) |
| AU (1) | AU2012342474A1 (pt) |
| BR (1) | BR112014012137A2 (pt) |
| CA (1) | CA2856325A1 (pt) |
| IL (1) | IL232399A0 (pt) |
| MX (1) | MX2014005855A (pt) |
| RU (1) | RU2014125143A (pt) |
| SG (2) | SG11201401973TA (pt) |
| WO (1) | WO2013076186A1 (pt) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| EP2790731A2 (de) * | 2011-12-14 | 2014-10-22 | Seattle Genetics, Inc. | Fgfr-binder-wirkstoff konjugate und ihre verwendung |
| EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
| WO2014113729A2 (en) * | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
| HUE058243T2 (hu) | 2013-08-01 | 2022-07-28 | Five Prime Therapeutics Inc | Afukozilált, FGFR2IIIB elleni antitestek |
| AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
| EP3134115A4 (en) | 2014-04-25 | 2017-10-25 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| JP6974943B2 (ja) | 2014-05-13 | 2021-12-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用 |
| ES2912567T3 (es) | 2014-09-26 | 2022-05-26 | Janssen Pharmaceutica Nv | Uso de paneles de genes mutantes de FGFR en la identificación de pacientes con cáncer que serán responsable al tratamiento con un inhibidor de FGFR |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| TW201642904A (zh) * | 2015-04-08 | 2016-12-16 | 第一三共股份有限公司 | 含抗ｆｇｆｒ２抗體及其他藥劑之組成物 |
| WO2016171107A1 (ja) * | 2015-04-20 | 2016-10-27 | 第一三共株式会社 | Ｆｇｆｒ２の検出 |
| CN108025084A (zh) | 2015-06-22 | 2018-05-11 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc） |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| RU2745707C2 (ru) | 2015-11-23 | 2021-03-30 | Файв Прайм Терапьютикс, Инк. | Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака |
| CA3007644A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
| EP3432934B1 (de) | 2016-03-24 | 2022-02-23 | Bayer Pharma Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| EP3471776B1 (en) | 2016-06-15 | 2022-05-04 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies |
| CN107513106A (zh) * | 2016-06-17 | 2017-12-26 | 艾托金生物医药（苏州）有限公司 | 抗FGFR2-IIIc单克隆抗体、杂交瘤细胞株和应用 |
| AU2017303205A1 (en) * | 2016-07-29 | 2019-01-17 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity |
| WO2018060688A1 (en) * | 2016-09-27 | 2018-04-05 | The University Of The Highlands And Islands | Antigen biomarkers |
| WO2018114798A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
| EP3558388A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
| SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| CN111108202A (zh) | 2017-09-29 | 2020-05-05 | 中外制药株式会社 | 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂 |
| WO2019246572A1 (en) * | 2018-06-22 | 2019-12-26 | Children's Medical Center Corporation | Compositions and methods for treating primary aldosteonism |
| KR20210064274A (ko) | 2018-09-21 | 2021-06-02 | 얀센 파마슈티카 엔.브이. | 담관암종의 치료 |
| JP2023508173A (ja) * | 2019-12-24 | 2023-03-01 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | 新規抗ＦＧＦＲ２ｂ抗体 |
| AU2021284297A1 (en) * | 2020-06-03 | 2023-02-02 | Dana-Farber Cancer Institute, Inc. | Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same |
| JP2023547323A (ja) | 2020-10-22 | 2023-11-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｆｇｆｒ２抗体及びその使用方法 |
| WO2023113806A1 (en) | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Recombinant aav for treatment of neural disease |
| EP4323531A1 (en) | 2021-04-12 | 2024-02-21 | Affinia Therapeutics Inc. | Recombinant aav for treatment of neural disease |
| IL308404A (en) | 2021-04-27 | 2024-01-01 | Generation Bio Co | Non-viral DNA vectors expressing therapeutic antibodies and uses thereof |
| WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
| CN117917435A (zh) * | 2022-10-21 | 2024-04-23 | 北京天广实生物技术股份有限公司 | 结合fgfr2b的抗体及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2005066211A2 (en) * | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| CA2655504A1 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| BRPI0917315B8 (pt) * | 2008-11-07 | 2021-05-25 | Galaxy Biotech Llc | anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo |
| WO2010105426A1 (zh) | 2009-03-19 | 2010-09-23 | 华为技术有限公司 | 一种线性分组码编码的方法和装置 |
| RU2012153241A (ru) * | 2010-05-11 | 2014-06-20 | Авео Фармасьютикалз, Инк. | Антитела к fgfr2 |
-
2012
- 2012-11-21 AR ARP120104379A patent/AR088941A1/es active Pending
- 2012-11-22 SG SG11201401973TA patent/SG11201401973TA/en unknown
- 2012-11-22 RU RU2014125143/10A patent/RU2014125143A/ru not_active Application Discontinuation
- 2012-11-22 BR BR112014012137A patent/BR112014012137A2/pt not_active IP Right Cessation
- 2012-11-22 US US14/359,663 patent/US20140322220A1/en not_active Abandoned
- 2012-11-22 AU AU2012342474A patent/AU2012342474A1/en not_active Abandoned
- 2012-11-22 SG SG10201603880WA patent/SG10201603880WA/en unknown
- 2012-11-22 CA CA2856325A patent/CA2856325A1/en not_active Abandoned
- 2012-11-22 WO PCT/EP2012/073325 patent/WO2013076186A1/en active Application Filing
- 2012-11-22 CN CN201280067865.9A patent/CN104066750B/zh not_active Expired - Fee Related
- 2012-11-22 MX MX2014005855A patent/MX2014005855A/es unknown
- 2012-11-22 KR KR1020147016644A patent/KR20140102698A/ko not_active Application Discontinuation
- 2012-11-22 JP JP2014542825A patent/JP2015504434A/ja not_active Ceased
- 2012-11-22 EP EP12794685.3A patent/EP2782934A1/en not_active Withdrawn
-
2014
- 2014-04-30 IL IL232399A patent/IL232399A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL232399A0 (en) | 2014-06-30 |
| SG10201603880WA (en) | 2016-07-28 |
| RU2014125143A (ru) | 2015-12-27 |
| US20140322220A1 (en) | 2014-10-30 |
| SG11201401973TA (en) | 2014-09-26 |
| AU2012342474A1 (en) | 2014-05-22 |
| AR088941A1 (es) | 2014-07-16 |
| NZ624534A (en) | 2016-06-24 |
| JP2015504434A (ja) | 2015-02-12 |
| CN104066750B (zh) | 2017-05-17 |
| MX2014005855A (es) | 2014-07-30 |
| CN104066750A (zh) | 2014-09-24 |
| EP2782934A1 (en) | 2014-10-01 |
| WO2013076186A1 (en) | 2013-05-30 |
| KR20140102698A (ko) | 2014-08-22 |
| CA2856325A1 (en) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR23C1023I2 (fr) | Anticorps anti-il-36r | |
| IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
| DK2934584T3 (da) | Anti-gdf15-antistoffer | |
| BR112012030311A2 (pt) | anticorpo | |
| DK2785375T3 (da) | Anti-pd-l1-antistoffer og anvendelser deraf | |
| CO7071096A2 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| DK2850101T3 (da) | Anti-FcRn-antistoffer | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| DK3275892T3 (da) | Præfusions-rsv-f-antigener | |
| DK3556774T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| BR112015002193A2 (pt) | anticorpos anti-etbr e imunoconjugados | |
| CR20140127A (es) | Anticuerpo anti-abtcr | |
| EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
| DK3467500T3 (da) | Cobinder-understøttede assayfremgangsmåder | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| BR112014002399A2 (pt) | conjunto | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| BR112014025037A2 (pt) | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente | |
| CO6791565A2 (es) | Anticuerpos anti-notch1 | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
| DK3202789T3 (da) | Anti-vla-4-antistoffer | |
| DK2828292T3 (da) | Jcv-neutraliserende antistoffer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |